Antibody Therapeutics : Impact Factor & More
eISSN: 2516-4236
Open AccessShare this on:
Key Metrics
CiteScore 
5
SJR
Q3Immunology
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Antibody Therapeutics
Antibody Therapeutics Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 1750 | USD 2625 |
| Publication Time | 8 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Antibody Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Antibody Therapeutics
Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies
- 1 Dec 2025
- Antibody Therapeutics
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study
- 20 Nov 2025
- Antibody Therapeutics
Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation
- 4 Nov 2025
- Antibody Therapeutics
The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity
- 1 Nov 2025
- Antibody Therapeutics
Overcoming antigen tolerance to develop GB22–45-2, an anti-DKK1 antibody for gastric cancer
- 30 Oct 2025
- Antibody Therapeutics
RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy
- 30 Oct 2025
- Antibody Therapeutics
Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies
- 1 Dec 2025
- Antibody Therapeutics
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study
- 20 Nov 2025
- Antibody Therapeutics
Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation
- 4 Nov 2025
- Antibody Therapeutics
The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity
- 1 Nov 2025
- Antibody Therapeutics
Overcoming antigen tolerance to develop GB22–45-2, an anti-DKK1 antibody for gastric cancer
- 30 Oct 2025
- Antibody Therapeutics
RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy
- 30 Oct 2025
- Antibody Therapeutics
FAQs on Antibody Therapeutics
How many articles did Antibody Therapeutics publish last year? 
What is Citescore for Antibody Therapeutics?
What is the SJR for Antibody Therapeutics?
Who is the publisher of Antibody Therapeutics?
